REMOVING BARRIERS TO PSYCHEDELIC DRUGS AS POTENTIAL TREATMENT FOR SERIOUS MENTAL ILLNESS: Today, President Donald J. Trump signed an Executive Order that will accelerate access to treatments for patients with serious mental illness, reaffirming his commitment to advancing solutions that provide hope to Americans with devastating, complex, and treatment-resistant conditions.

• The Order directs the Food and Drug Administration (FDA) Commissioner to provide Commissioner’s National Priority Vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designations for treating serious mental illnesses, and that meet the criteria of the National Priority Voucher Program. This will ensure that red tape does not delay the FDA’s gold standard review of any potential therapy.

• The Order further directs the FDA and the Drug Enforcement Agency to establish a pathway for eligible patients to access investigational psychedelic drugs, including ibogaine compounds, that are under FDA review and that have met basic safety requirements under President Trump’s landmark Right to Try Act.

• The Order requires the Secretary of Health and Human Services (HHS) to allocate $50 million through the Advanced Research Projects for Health (ARPA-H) program to match investments made by state governments to advance research into psychedelic programs for populations with serious mental illness.

• The Order requires HHS and the FDA to collaborate with the Department of Veterans Affairs and the private sector to increase clinical trial participation and evidence generation surrounding experimental psychedelic therapies.
• The Order directs the Attorney General to initiate reviews of relevant products upon successful completion of their Phase 3 clinical trials so that they can be rescheduled as soon as possible upon FDA approval, where appropriate.

https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/